<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VERAPAMIL HYDROCHLORIDEÂ - verapamil hydrochlorideÂ tablet, film coated, extended releaseÂ </strong><br>Blenheim Pharmacal, Inc.<br></p></div>
<h1>VERAPAMIL HCl EXTENDED-RELEASE TABLETS USP<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_inv-0504a3f2-5f7e-420a-acc8-b00c8c27caf8"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist).</p>
<p>The tablets are designed for extended-release of the drug in the gastrointestinal tract; extended-release characteristics are not altered when the tablet is divided in half. Verapamil hydrochloride is not chemically related to other cardioactive drugs.</p>
<p>Verapamil hydrochloride is chemically designated as Benzeneacetonitrile, Î±-[3-[[2-(3,4- dimethoxyphenyl)ethyl]-methylamino]propyl]-3,4-dimethoxy-Î±-(1-methylethyl)-monohydrochloride and has the following structural formula:</p>
<div class="Figure"><img alt="Verapamil Hydrochloride Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=887b91f5-f117-47e6-8d59-87ac61d17175&amp;name=c213ffc9-152f-4c1c-a3ee-a5b638f6c717-01.jpg"></div>
<p>C<span class="Sub">27</span>H<span class="Sub">38</span>N<span class="Sub">2</span>O<span class="Sub">4</span>â—?HCl M.W. 491.07</p>
<p>Verapamil hydrochloride is a white or practically white crystalline powder, practically odorless with a bitter taste. It is soluble in water, methanol, and chloroform.</p>
<p>Each extended-release tablet, for oral administration, contains 240 mg, 180 mg or 120 mg verapamil hydrochloride. In addition to verapamil hydrochloride the tablets contain the following inactive ingredients: sodium alginate, microcrystalline cellulose, povidone, magnesium stearate. The coating for verapamil 240 mg tablets contains: hydroxypropyl cellulose, hypromellose, titanium dioxide, polyethylene glycol, D&amp;C Yellow No. 10 Aluminum lake. The coating for verapamil 180 mg tablets contains: hypromellose, titanium dioxide, polyethylene glycol, FD &amp; C Yellow No. 6 Aluminum lake, polysorbate 80. The coating for verapamil 120 mg tablets contains: hypromellose, titanium dioxide, polyethylene glycol, polydextrose powder, triacetin, synthetic yellow iron oxide.</p>
<p>All three strengths: 120 mg, 180 mg, and 240 mg meet USP Drug Release Test #2.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_inv-c86056d8-bd38-4586-99df-a89129dda0dc"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Verapamil HCl is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle as well as in conductile and contractile myocardial cells.</p>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_inv-4acd2779-7ce4-45e5-9f82-80c24dff7c38"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-adb12010-a6dd-4e2d-b16b-0fda30ec21c4"></a><a name="section-2.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">Essential Hypertension</span></h3>
<p class="First">Verapamil exerts antihypertensive effects by decreasing systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>, usually without orthostatic decreases in blood pressure or <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (rate less than 50 beats/min) is uncommon (1.4%). During isometric or dynamic exercise verapamil does not alter systolic cardiac function in patients with normal ventricular function.</p>
<p>Verapamil does not alter total serum calcium levels. However, one report suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-a9d967c5-50bd-461e-8d9a-a8d0a3aeeeea"></a><a name="section-2.1.2"></a><p></p>
<h3>Other Pharmacological Actions of Verapamil Include the Following</h3>
<p class="First">Verapamil dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary artery spasm</span>, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary artery spasm</span> and is responsible for the effectiveness of verapamil in vasospastic (Prinzmetal's or variant) as well as <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> at rest. Whether this effect plays any role in classical effort angina is not clear, but studies of exercise tolerance have not shown an increase in the maximum exercise rate-pressure product, a widely accepted measure of oxygen utilization. This suggests that, in general, relief of spasm or dilation of coronary arteries is not an important factor in classical angina.</p>
<p>Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.</p>
<p>Electrical activity through the AV node depends, to a significant degree, upon calcium influx through the slow channel. By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.</p>
<p>Normal sinus rhythm is usually not affected, but in patients with <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span>, verapamil may interfere with sinus node impulse generation and may induce <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span> or <span class="product-label-link" type="condition" conceptid="4277903" conceptname="Sinoatrial block">sinoatrial block</span>. <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Atrioventricular block</span> can occur in patients without preexisting conduction defects (see <span class="Bold">WARNINGS</span>).</p>
<p>Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers. Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract. Acceleration of ventricular rate and/or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> has been reported in patients with <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and a coexisting accessory AV pathway following administration of verapamil (see <span class="Bold">WARNINGS</span>).</p>
<p>Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. It is not known whether this action is important at the doses used in man.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_inv-5d8398e9-f188-428f-a69a-f3e7e467032d"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">With the immediate-release formulation, more than 90% of the orally administered dose of verapamil HCl Is absorbed. Because of rapid biotransformation of verapamil during its first pass through the portal circulation, bioavailability ranges from 20% to 35%. Peak plasma concentrations are reached between 1 and 2 hours after oral administration. Chronic oral administration of 120 mg of verapamil hydrochloride every 6 hours resulted in plasma levels of verapamil ranging from 125 to 400 ng/mL, with higher values reported occasionally. A nonlinear correlation between the verapamil dose administered and verapamil plasma levels does exist.</p>
<p>In early dose titration with verapamil a relationship exists between verapamil plasma concentrations and the prolongation of the PR interval. However, during chronic administration this relationship may disappear.</p>
<p>The mean elimination half-life in single-dose studies ranged from 2.8 to 7.4 hours. In these same studies, after repetitive dosing, the half-life increased to a range from 4.5 to 12 hours (after less than 10 consecutive doses given 6 hours apart). Half-life of verapamil may increase during titration. No relationship has been established between the plasma concentration of verapamil and a reduction in blood pressure.</p>
<p>Aging may affect the pharmacokinetics of verapamil. Elimination half-life may be prolonged in the elderly.</p>
<p>In multiple-dose studies under fasting conditions, the bioavailability, measured by AUC, of extended-release verapamil was similar to immediate release verapamil; rates of absorption were, of course, different.</p>
<p>In a randomized, single dose, crossover study using healthy volunteers, administration of verapamil hydrochloride extended-release tablets 240 mg with food produced peak plasma verapamil concentrations of 79 ng/mL, time to peak plasma verapamil concentration of 7.71 hours, and AUC<span class="Sub">(</span><span class="Sub">0-24hr</span><span class="Sub">)</span> of 841 ng-hr/mL. When verapamil hydrochloride extended-release tablets</p>
<p>were administered to fasting subjects, peak plasma verapamil concentration was 164 ng/mL; time to peak plasma verapamil concentration was 5.21 hours; and AUC<span class="Sub">(</span><span class="Sub">0-24hr</span><span class="Sub">)</span> was 1,478 ng-hr/mL.</p>
<p>Similar results were demonstrated for plasma norverapamil. Food thus produces decreased bioavailability (AUC) but a narrower peak-to-trough ratio. Good correlation of dose and response is not available, but controlled studies of extended-release verapamil have shown effectiveness of doses similar to the effective doses of immediate-release verapamil.</p>
<p>In healthy man, orally administered verapamil HCl undergoes extensive metabolism in the liver. Twelve metabolites have been identified in plasma; all except norverapamil are present in trace amounts only.</p>
<p>Norverapamil can reach steady-state plasma concentrations approximately equal to those of verapamil itself.</p>
<p>The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.</p>
<p>Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug. Approximately 90% is bound to plasma proteins. In patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours (see <span class="Bold">PRECAUTIONS</span>); the volume of distribution is increased and plasma clearance reduced to about 30% of normal. Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one-third of the oral daily dose required for patients with normal liver function.</p>
<p>After four weeks of oral dosing (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.</p>
<p>In ten healthy males, administration of oral verapamil (80 mg every 8 hours for 6 days) and a single oral dose of ethanol (0.8 g/kg) resulted in a 17% increase in mean peak ethanol concentrations (106.45 Â± 21.40 to 124.23 Â± 24.74 mgâ€¢hr/dL) compared to placebo. The area under the blood ethanol concentration versus time curve (AUC over 12 hours) increased by 30% (365.67 Â± 93.52 to 475.07 Â± 97.24 mgâ€¢hr/dL). Verapamil AUCs were positively correlated (r = 0.71) to increased ethanol blood AUC values (see <span class="Bold">PRECAUTIONS</span>, <span class="Bold">Drug Interactions</span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-dac7d33f-b5e6-472d-b090-daec68b0f080"></a><a name="section-2.3"></a><p></p>
<h2>Hemodynamics and Myocardial Metabolism</h2>
<p class="First">Verapamil reduces afterload and myocardial contractility. Improved left ventricular diastolic function in patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">IHSS</span> and those with coronary heart disease has also been observed with verapamil HCl therapy. In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> is usually not reduced. However, in patients with severe <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>, (e.g., pulmonary wedge pressure above 20 mm Hg or <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> less than 30%), or in patients taking beta-adrenergic blocking agents or other cardiodepressant drugs, deterioration of ventricular function may occur (see <span class="Bold">Drug Interactions</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-206b7d7a-6359-4168-ae77-5ebae4dd5ed1"></a><a name="section-2.4"></a><p></p>
<h2>Pulmonary Function</h2>
<p class="First">Verapamil does not induce broncho-constriction and, hence, does not impair ventilatory function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_inv-6d8e4279-2df9-438c-b380-4d2421367244"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Verapamil HCl Extended-Release Tablets are indicated for the management of <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_inv-88ef65e4-2c6a-457b-a5e6-2584d7497e9c"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Verapamil Hydrochloride Extended-Release Tablets are contraindicated in:</p>
<ol>
<li>Severe <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> (see <span class="Bold">WARNINGS</span>).</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (systolic pressure less than 90 mm Hg) or <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">Sick sinus syndrome</span> (except in patients with a functioning artificial ventricular pacemaker).</li>
<li>Second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> (except in patients with a functioning artificial ventricular pacemaker).</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and an accessory bypass tract (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes) (see <span class="Bold">WARNINGS</span>).</li>
<li>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to verapamil hydrochloride.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_inv-4a65212c-5273-4706-9918-1f16f699b8a1"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-ea91a3bc-f07e-41aa-8396-b9241ddf6282"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First">Verapamil has a negative inotropic effect, which in most patients is compensated by its afterload reduction (decreased systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>) properties without a net impairment of ventricular performance. In clinical experience with 4,954 patients, 87 (1.8%) developed <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>. Verapamil should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> (e.g., <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> less than 30%, or moderate to severe symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>) and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker (see <span class="Bold">Drug Interactions</span>).</p>
<p>Patients with milder ventricular dysfunction should, if possible, be controlled with optimum doses of digitalis and/or diuretics before verapamil treatment. (<span class="Bold">Note interactions with digoxin under PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-85c5ca5f-45c6-420f-9466-564f1ef2d808"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">Occasionally, the pharmacologic action of verapamil may produce a decrease in blood pressure below normal levels, which may result in <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The incidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> observed in 4,954 patients enrolled in clinical trials was 2.5%. In hypertensive patients, decreases in blood pressure below normal are unusual. Tilt-table testing (60 degrees) was not able to induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-fe940fc6-4d23-45bb-b4be-b3d6a83a538f"></a><a name="section-5.3"></a><p></p>
<h2>Elevated Liver Enzymes</h2>
<p class="First">Elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have been reported. Such elevations have sometimes been transient and may disappear even in the face of continued verapamil treatment. Several cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular injury</span> related to verapamil have been proven by rechallenge; half of these had clinical symptoms (<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and/or <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">right upper quadrant pain</span>) in addition to elevations of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, and alkaline phosphatase. Periodic monitoring of liver function in patients receiving verapamil is therefore prudent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-111dd9e6-65b4-45ea-8d32-5cf214b0ce77"></a><a name="section-5.4"></a><p></p>
<h2>Accessory Bypass Tract (Wolff-Parkinson-White or Lown-Ganong-Levine)</h2>
<p class="First">Some patients with paroxysmal and/or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span> or <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> and a coexisting accessory AV pathway have developed increased antegrade conduction across the accessory pathway bypassing the AV node, producing a very rapid ventricular response or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> after receiving intravenous verapamil (or digitalis).</p>
<p>Although a risk of this occurring with oral verapamil has not been established, such patients receiving oral verapamil may be at risk and its use in these patients is contraindicated (see <span class="Bold">CONTRAINDICATIONS</span>).</p>
<p>Treatment is usually DC-cardioversion. Cardioversion has been used safely and effectively after oral verapamil hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-e4e173b8-7f7e-4427-9b8e-c8bdacd8a130"></a><a name="section-5.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Atrioventricular Block</span></h2>
<p class="First">The effect of verapamil on AV conduction and the SA node may cause asymptomatic first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> and transient <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, sometimes accompanied by nodal escape rhythms. PR-interval prolongation is correlated with verapamil plasma concentrations, especially during the early titration phases of therapy. Higher degrees of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, however, were infrequently (0.8%) observed. Marked first-degree block or progressive development to second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> requires a reduction in dosage or, in rare instances, discontinuation of verapamil HCl and institution of appropriate therapy, depending upon the clinical situation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-54f8adae-c9ea-4694-8964-df98194366c0"></a><a name="section-5.6"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">Hypertrophic Cardiomyopathy</span> (<span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">IHSS</span>)</h2>
<p class="First">In 120 patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> most of them refractory or intolerant to propranolol) who received therapy with verapamil at doses up to 720 mg/day, a variety of serious adverse effects were seen. Three patients died in <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>; all had severe left ventricular outflow obstruction and a past history of <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>. Eight other patients had <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> and/or severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; abnormally high (greater than 20 mm Hg) pulmonary wedge pressure and a marked left ventricular outflow obstruction were present in most of these patients. Concomitant administration of quinidine (see <span class="Bold">Drug Interactions</span>) preceded the severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in 3 of the 8 patients (2 of whom developed <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>). <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span> occurred in 11% of the patients, second-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> in 4% and <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span> in 2%. It must be appreciated that this group of patients had a serious disease with a high mortality rate. Most adverse effects responded well to dose reduction, and only rarely did verapamil have to be discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_inv-8849a75b-a305-466a-bd3c-00971ff88b8a"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_inv-11d19160-11ba-434d-bfb2-792ad9782860"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-f4845571-09e0-4644-ada7-b3200080b647"></a><a name="section-6.1.1"></a><p></p>
<h3>Use in Patients with Impaired Hepatic Function</h3>
<p class="First">Since verapamil is highly metabolized by the liver, it should be administered cautiously to patients with impaired hepatic function. Severe liver dysfunction prolongs the elimination half-life of immediate-release verapamil to about 14 to 16 hours; hence, approximately 30% of the dose given to patients with normal liver function should be administered to these patients. Careful monitoring for abnormal prolongation of the PR interval or other signs of excessive pharmacologic effects (see <span class="Bold">OVERDOSAGE</span>) should be carried out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-31da2406-c900-45ff-a0f4-c3c45759874b"></a><a name="section-6.1.2"></a><p></p>
<h3>Use in Patients with Attenuated (Decreased) Neuromuscular Transmission</h3>
<p class="First">It has been reported that verapamil decreases neuromuscular transmission in patients with Duchenne's <span class="product-label-link" type="condition" conceptid="4247802" conceptname="Muscular dystrophy">muscular dystrophy</span>, prolongs recovery from the neuromuscular blocking agent vecuronium, and causes a worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. It may be necessary to decrease the dosage of verapamil when it is administered to patients with attenuated neuromuscular transmission.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-147c8b4b-642b-44a2-8a50-caaa1c299f77"></a><a name="section-6.1.3"></a><p></p>
<h3>Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h3>
<p class="First">About 70% of an administered dose of verapamil is excreted as metabolites in the urine. Verapamil is not removed by hemodialysis. Until further data are available, verapamil should be administered cautiously to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>These patients should be carefully monitored for abnormal prolongation of the PR interval or other signs of overdosage (see <span class="Bold">OVERDOSAGE</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_inv-f4a5fb47-47f1-493e-9e38-c2307161672c"></a><a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-1b041d63-d66e-4763-a167-2d2a22101e1f"></a><a name="section-6.2.1"></a><p></p>
<h3>Telithromycin</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and bradyarrythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fdc71085-e82e-4e8d-b2d1-9be039e5187f"></a><a name="section-6.2.2"></a><p></p>
<h3>Clonidine</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span> resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. Monitor heart rate in patients receiving concomitant verapamil and clonidine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-f8b16af8-2be4-4338-a0a7-95e6da8cf785"></a><a name="section-6.2.3"></a><p></p>
<h3>Cytochrome Inducers/Inhibitors</h3>
<p class="First"><span class="Italics">In vitro</span> metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYP1A2, CYP2C8, CYP2C9 and CYP2C18. Clinically significant interactions have been reported with inhibitors of CYP3A4 (eg, erythromycin, ritonavir) causing elevation of plasma levels of verapamil while inducers of CYP3A4 (eg, rifampin) have caused a lowering of plasma levels of verapamil; therefore, patients should be monitored for drug interactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-5646977c-a664-4ca7-a08c-30800267ab1e"></a><a name="section-6.2.4"></a><p></p>
<h3>Aspirin</h3>
<p class="First">In a few reported cases, coadministration of verapamil with aspirin has led to increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding times</span> greater than observed with aspirin alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-bc9b26c0-02e1-4813-899a-5fc0ab294df7"></a><a name="section-6.2.5"></a><p></p>
<h3>Grapefruit Juice</h3>
<p class="First">The intake of grapefruit juice may increase drug levels of verapamil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-b63abbc4-8417-4efd-91ce-3e70629f7328"></a><a name="section-6.2.6"></a><p></p>
<h3>Beta-Blockers</h3>
<p class="First">Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility. The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied. However, there have been reports of excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, including <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span>, when the combination has been used for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. For hypertensive patients, the risks of combined therapy may outweigh the potential benefits. The combination should be used only with caution and close monitoring.</p>
<p>Asymptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (36 beats/min) with a <span class="product-label-link" type="condition" conceptid="4111551" conceptname="Wandering atrial pacemaker">wandering atrial pacemaker</span> has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.</p>
<p>A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil. A variable effect has been seen when verapamil and atenolol were given together.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-6885c684-217c-4fdc-926c-8cff37c69809"></a><a name="section-6.2.7"></a><p></p>
<h3>Digitalis</h3>
<p class="First">Clinical use of verapamil in digitalized patients has shown the combination to be well tolerated if digoxin doses are properly adjusted. Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. In patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> the influence of verapamil on digoxin kinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. Maintenance digitalization doses should be reduced when verapamil is administered, and the patient should be carefully monitored to avoid over- or underdigitalization. Whenever overdigitalization is suspected, the daily dose of digitalis should be reduced or temporarily discontinued. Upon discontinuation of verapamil HCl use, the patient should be reassessed to avoid underdigitalization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-69b279d0-1f06-4764-aa5a-e4e3de8358c0"></a><a name="section-6.2.8"></a><p></p>
<h3>Antihypertensive Agents</h3>
<p class="First">Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure. Patients receiving these combinations should be appropriately monitored. Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients. Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-1946d650-7333-4306-9bc0-492ebf755908"></a><a name="section-6.2.9"></a><p></p>
<h3>Antiarrhythmic Agents</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_620e9bb8-b2f4-4075-b955-d1391f9fb188"></a><a name="section-6.2.9.1"></a><p></p>
<h4>Disopyramide</h4>
<p class="First">Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_279aab85-36a6-4336-a233-cd500208cf64"></a><a name="section-6.2.9.2"></a><p></p>
<h4>Flecainide</h4>
<p class="First">A study of healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27e9a385-0e84-4b38-ab2e-12f1b9460d28"></a><a name="section-6.2.9.3"></a><p></p>
<h4>Quinidine</h4>
<p class="First">In a small number of patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> (<span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">IHSS</span>), concomitant use of verapamil and quinidine resulted in significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Until further data are obtained, combined therapy of verapamil and quinidine in patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> should probably be avoided.</p>
<p>The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients.</p>
<p>Verapamil significantly counteracted the effects of quinidine on AV conduction. There has been a report of increased quinidine levels during verapamil therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8c47cf3-96b4-4c83-9238-93893ecc7654"></a><a name="section-6.2.9.4"></a><p></p>
<h4>Nitrates</h4>
<p class="First">Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions. The pharmacologic profile of both drugs and the clinical experience suggest beneficial interactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2f496c77-2281-45a8-81bb-7bddc54f4af0"></a><a name="section-6.2.10"></a><p></p>
<h3>Other</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b7f6134-567e-4681-a1de-e06a44369c8e"></a><a name="section-6.2.10.1"></a><p></p>
<h4>Alcohol</h4>
<p class="First">Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol (see <span class="Bold">CLINICAL PHARMACOLOGY</span>, <span class="Bold">Pharmacokinetics and Metabolism</span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3db431d-3a59-434f-8297-748a62c840b6"></a><a name="section-6.2.10.2"></a><p></p>
<h4>Cimetidine</h4>
<p class="First">The interaction between cimetidine and chronically administered verapamil has not been studied. Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77d80d07-2bee-4ebc-bf9a-ea0784587346"></a><a name="section-6.2.10.3"></a><p></p>
<h4>Lithium</h4>
<p class="First">Increased sensitivity to the effects of lithium (<span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>) has been reported during concomitant verapamil-lithium therapy; lithium levels have been observed sometimes to increase, sometimes to decrease, and sometimes to be unchanged. Patients receiving both drugs must be monitored carefully.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d76e4201-fef8-4522-8d0a-426f27e9b865"></a><a name="section-6.2.10.4"></a><p></p>
<h4>Carbamazepine</h4>
<p class="First">Verapamil may increase carbamazepine concentrations during combined therapy. This may produce carbamazepine side effects such as <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13904aa7-3fad-44a8-96a4-fb4e346d0b3e"></a><a name="section-6.2.10.5"></a><p></p>
<h4>Rifampin</h4>
<p class="First">Therapy with rifampin may markedly reduce oral verapamil bioavailability.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31825894-3685-4067-9e15-d8e4b61e1cb8"></a><a name="section-6.2.10.6"></a><p></p>
<h4>Phenobarbital</h4>
<p class="First">Phenobarbital therapy may increase verapamil clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f60d67a-ddea-45f5-aa88-8b3e57a4e17e"></a><a name="section-6.2.10.7"></a><p></p>
<h4>Cyclosporine</h4>
<p class="First">Verapamil therapy may increase serum levels of cyclosporine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3db5dc9f-d283-469e-84b0-718b663db517"></a><a name="section-6.2.10.8"></a><p></p>
<h4>Theophylline</h4>
<p class="First">Verapamil therapy may inhibit the clearance and increase the plasma levels of theophylline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_72fe26ec-9376-4d15-b45e-d916d78c2920"></a><a name="section-6.2.10.9"></a><p></p>
<h4>Inhalation Anesthetics</h4>
<p class="First">Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_432df985-a2d2-4d19-8fcf-33ab2d5ffa43"></a><a name="section-6.2.10.10"></a><p></p>
<h4>Neuromuscular-Blocking Agents</h4>
<p class="First">Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_inv-9f39dd3d-111a-47d6-a610-ad9ea21a1ef3"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">An 18-month toxicity study in rats, at a low multiple (6-fold) of the maximum recommended human dose, and not the maximum tolerated dose, did not suggest a tumorigenic potential. There was no evidence of a carcinogenic potential of verapamil administered in the diet of rats for two years at doses of 10, 35, and 120 mg/kg/day or approximately 1, 3.5, and 12 times, respectively, the maximum recommended human daily dose (480 mg/day or 9.6 mg/kg/day).</p>
<p>Verapamil was not mutagenic in the Ames test in 5 test <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> at 3 mg per plate with or without metabolic activation.</p>
<p>Studies in female rats at daily dietary doses up to 5.5 times (55 mg/kg/day) the maximum recommended human dose did not show impaired fertility. Effects on male fertility have not been determined.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_inv-2dcfad24-0325-422d-ada2-44af1f8541db"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_inv-98fa5705-c547-4448-b575-a940250475e8"></a><a name="section-6.4.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Reproduction studies have been performed in rabbits and rats at oral doses up to 1.5 (15 mg/kg/day) and 6 (60 mg/kg/day) times the human oral daily dose, respectively, and have revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. In the rat, however, this multiple of the human dose was embryocidal and retarded fetal growth and development, probably because of adverse maternal effects reflected in reduced <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gains</span> of the dams.</p>
<p>This oral dose has also been shown to cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in rats. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Verapamil crosses the placental barrier and can be detected in umbilical vein blood at delivery.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_inv-0374b443-d44a-4ede-b4cf-a4b326d9caff"></a><a name="section-6.5"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">It is not known whether the use of verapamil during labor or delivery has immediate or delayed adverse effects on the fetus, or whether it prolongs the duration of labor or increases the need for forceps delivery or other obstetric intervention. Such adverse experiences have not been reported in the literature, despite a long history of use of verapamil in Europe in the treatment of cardiac side effects of beta-adrenergic agonist agents used to treat <span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_inv-801b3513-9681-4640-bd04-4c87d7b7b725"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Verapamil is excreted in human milk. Because of the potential for adverse reactions in nursing infants from verapamil, nursing should be discontinued while verapamil is administered.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_inv-a9fe8292-2661-43e2-a6be-0efc6939aed1"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and efficacy of verapamil HCl in children below the age of 18 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_inv-56bc2777-6f91-47f9-939e-8d56a492ef34"></a><a name="section-6.8"></a><p></p>
<h2>Animal Pharmacology and/or Animal Toxicology</h2>
<p class="First">In chronic animal toxicology studies, verapamil caused lenticular and/or suture line changes at 30 mg/kg/day or greater, and frank <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> at 62.5 mg/kg/day or greater in the beagle dog but not in the rat.</p>
<p>Development of <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> due to verapamil has not been reported in man.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_inv-aa3f4211-9ca0-4766-8cc4-2991ddc7f5fc"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Serious adverse reactions are uncommon when verapamil therapy is initiated with upward dose titration within the recommended single and total daily dose. See <span class="Bold">WARNINGS </span>for discussion of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, elevated liver enzymes, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, and rapid ventricular response. Reversible (upon discontinuation of verapamil) non-obstructive, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> has been infrequently reported in association with the use of verapamil. The following reactions to orally administered verapamil occurred at rates greater than 1% or occurred at lower rates but appeared clearly drug-related in clinical trials in 4,954 patients.</p>
<a name="inv-237a93e5-9fd4-4f13-aa8a-1523acb5ca9d"></a><table border="1" width="418.000">
<col width="45.0%">
<col width="55.0%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="left" valign="middle">7.3%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="left" valign="middle">3.3%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="left" valign="middle">2.7%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Botrule Rrule" align="left" valign="middle">2.5%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="left" valign="middle">2.2%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Botrule Rrule" align="left" valign="middle">1.9%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle">CHF/<span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary Edema</span></td>
<td class="Botrule Rrule" align="left" valign="middle">1.8%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Rrule" align="left" valign="middle">1.7%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Botrule Rrule" align="left" valign="middle">1.4%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> (HR &lt; 50/min)</td>
<td class="Botrule Rrule" align="left" valign="middle">1.4%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> - total (1Â°,2Â°,3Â°)</td>
<td class="Botrule Rrule" align="left" valign="middle">1.2%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle">2Â°and 3Â°</td>
<td class="Botrule Rrule" align="left" valign="middle">0.8%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Rrule" align="left" valign="middle">1.2%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Botrule Rrule" align="left" valign="middle">0.6%</td>
</tr>
</tbody>
</table>
<p>Elevated liver enzymes (see <span class="Bold">WARNINGS</span>)</p>
<p>In clinical trials related to the control of ventricular response in digitalized patients who had <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> or <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>, ventricular rates below 50/min at rest occurred in 15% of patients and asymptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred in 5% of patients.</p>
<p>The following reactions, reported in 1% or less of patients, occurred under conditions (open trials, marketing experience) where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship:</p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, atrioventricular dissociation, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold">Digestive System: </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, gastrointestinal distress, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>.</p>
<p><span class="Bold">Hemic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>.</p>
<p><span class="Bold">Nervous System</span>: <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, equilibrium disorders, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>.</p>
<p><span class="Bold">Skin: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">exanthema</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>, <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span>, maculas, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>.</p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Bold">Urogenital: </span><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>/<span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span>, increased urination, spotty menstruation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-dc40655a-decf-48a0-ba31-9240a2bd170d"></a><a name="section-7.1"></a><p></p>
<h2>Treatment of Acute Cardiovascular Adverse Reactions</h2>
<p class="First">The frequency of cardiovascular adverse reactions which require therapy is rare; hence, experience with their treatment is limited. Whenever severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or complete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> occurs following oral administration of verapamil, the appropriate emergency measures should be applied immediately; e.g., intravenously administered isoproterenol HCl, norepinephrine bitartrate, atropine sulfate (all in the usual doses), or calcium gluconate (10% solution). In patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> (<span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">IHSS</span>), alpha-adrenergic agents (phenylephrine HCl, metaraminol bitartrate or methoxamine HCl) should be used to maintain blood pressure, and isoproterenol and norepinephrine should be avoided. If further support is necessary, dopamine HCl or dobutamine HCl may be administered. Actual treatment and dosage should depend on the severity of the clinical situation and the judgment and experience of the treating physician.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_inv-793ea3c2-e4ce-4ca5-97ba-a364ad4e3d55"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> with verapamil may lead to pronounced <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and conduction system abnormalities (e.g., <span class="product-label-link" type="condition" conceptid="4038688" conceptname="AV junctional rhythm">junctional rhythm</span> with <span class="product-label-link" type="condition" conceptid="4175473" conceptname="Atrioventricular dissociation">AV dissociation</span> and high degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, including <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>). Other symptoms secondary to <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> (e.g., <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, renal dysfunction, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>) may be evident.</p>
<p>Treat all verapamil <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> as serious and maintain observation for at least 48 hours (especially extended-release verapamil), preferably under continuous hospital care. Delayed pharmacodynamic consequences may occur with the extended-release formulation. Verapamil is known to decrease gastrointestinal transit time.</p>
<p>In <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, tablets of verapamil extended-release have occasionally been reported to form concretions within the stomach or intestines. These concretions have not been visible on plain radiographs of the abdomen, and no medical means of gastrointestinal emptying is of proven efficacy in removing them.</p>
<p>Endoscopy might reasonably be considered in cases of massive <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> when symptoms are unusually prolonged.</p>
<p>Treatment of overdosage should be supportive. Beta-adrenergic stimulation or parenteral administration of calcium injections may increase calcium ion flux across the slow channel and have been used effectively in treatment of deliberate overdosage with verapamil. Continued treatment with large doses of calcium may produce a response. In a few reported cases, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with calcium channel blockers that was initially refractory to atropine became more responsive to this treatment when the patients received large doses (close to 1 gram/hour for more than 24 hours) of calcium chloride. Verapamil cannot be removed by hemodialysis. Clinically significant hypotensive reactions or high-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> should be treated with vasopressor agents or cardiac pacing, respectively. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Asystole</span> should be handled by the usual measures, including cardiopulmonary resuscitation.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_inv-171a70ac-47ac-4a51-87a5-b645302f9048"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-59dc2f84-7ed6-4b17-812a-6192f02cede0"></a><a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">Essential hypertension</span></h2>
<p class="First">The dose of verapamil HCl extended-release should be individualized by titration and the drug should be administered with food. Initiate therapy with 180 mg of extended-release verapamil HCl given in the morning. Lower initial doses of 120 mg a day may be warranted in patients who may have an increased response to verapamil (e.g., the elderly or small people etc.). Upward titration should be based on therapeutic efficacy and safety evaluated weekly and approximately 24 hours after the previous dose. The antihypertensive effects of verapamil HCl extended-release are evident within the first week of therapy.</p>
<p>If adequate response is not obtained with 180 mg of verapamil HCl extended-release, the dose may be titrated upward in the following manner:</p>
<ol>
<li>240 mg each morning,</li>
<li>180 mg each morning plus 180 mg each evening; or 240 mg each morning plus 120 mg each evening,</li>
<li>240 mg every twelve hours.</li>
</ol>
<p>When switching from immediate release verapamil to extended-release verapamil, the total daily dose in milligrams may remain the same.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_inv-3efcd9b9-2c71-483d-b4ce-372ca9d4ff1f"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Verapamil Hydrochloride Extended-Release Tablets USP 120 mg are supplied as ivory, round, unscored, film-coated tablets debossed with â€œ120â€? on one side</p>
<div class="Figure"><img alt="Company logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=887b91f5-f117-47e6-8d59-87ac61d17175&amp;name=c213ffc9-152f-4c1c-a3ee-a5b638f6c717-02.jpg"></div>
<p>on the other side, packaged in bottles of 100 tablets and unit-dose boxes of 100 tablets.</p>
<p>Verapamil Hydrochloride Extended-Release Tablets USP 180 mg are supplied as light orange, capsule-shaped, scored, film-coated tablets debossed with â€œ7301â€? on one side,</p>
<div class="Figure"><img alt="Company logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=887b91f5-f117-47e6-8d59-87ac61d17175&amp;name=c213ffc9-152f-4c1c-a3ee-a5b638f6c717-03.jpg"></div>
<p>on the other side, packaged in bottles of 100, 500 tablets and unit-dose boxes of 100 tablets.</p>
<p>Verapamil Hydrochloride Extended-Release Tablets USP 240 mg are supplied as ivory, capsule-shaped, scored, film-coated tablets debossed with â€œ7300â€? on one side,</p>
<div class="Figure"><img alt="Company logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=887b91f5-f117-47e6-8d59-87ac61d17175&amp;name=c213ffc9-152f-4c1c-a3ee-a5b638f6c717-04.jpg"></div>
<p>on the other side, packaged in bottles of 100, 500 tablets and unit-dose boxes of 100 tablets.</p>
<p>Store between 20Ëš to 25Ëš C (68Ëš to 77Ëš F) [See USP Controlled Room Temperature]. </p>
<p>PROTECT FROM LIGHT AND MOISTURE</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). </p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. </p>
<p>You may report side effects to FDA at <span class="Bold">1-800-FDA-1088</span></p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. D 4/2010</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<p class="First">10544-541-30 Bottle Label<img alt="Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=887b91f5-f117-47e6-8d59-87ac61d17175&amp;name=10544-541-30%20-%200172-4280-70.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VERAPAMIL HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">verapamil hydrochloride tablet, film coated, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10544-541(NDC:0172-4280)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VERAPAMIL HYDROCHLORIDE</strong> (VERAPAMIL) </td>
<td class="formItem">VERAPAMIL HYDROCHLORIDE</td>
<td class="formItem">240Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ALGINATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (ivory) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">7300</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10544-541-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA073568</td>
<td class="formItem">08/20/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Blenheim Pharmacal, Inc.
							(171434587)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Blenheim Pharmacal, Inc. (171434587)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Blenheim Pharmacal, Inc.</td>
<td class="formItem"></td>
<td class="formItem">171434587</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3035088e-c702-4fbc-a024-16121a2f9b8a</div>
<div>Set id: 887b91f5-f117-47e6-8d59-87ac61d17175</div>
<div>Version: 1</div>
<div>Effective Time: 20100820</div>
</div>
</div>Â <div class="DistributorName">Blenheim Pharmacal, Inc.</div></p>
</body></html>
